Fox Run Management L.L.C. Invests $365,000 in Zai Lab Limited (NASDAQ:ZLAB)

Fox Run Management L.L.C. bought a new stake in Zai Lab Limited (NASDAQ:ZLAB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,946 shares of the company’s stock, valued at approximately $365,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ZLAB. US Bancorp DE grew its stake in Zai Lab by 1,671.9% in the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after purchasing an additional 5,534 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Zai Lab in the 3rd quarter valued at approximately $225,000. Daiwa Securities Group Inc. boosted its holdings in shares of Zai Lab by 4,851.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock valued at $231,000 after buying an additional 9,364 shares during the last quarter. RBF Capital LLC acquired a new position in Zai Lab during the third quarter worth $241,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Zai Lab by 15.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company’s stock worth $290,000 after buying an additional 1,502 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a research report on Tuesday, March 4th. Scotiabank began coverage on Zai Lab in a report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, March 13th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Insider Buying and Selling at Zai Lab

In related news, insider Rafael Amado sold 3,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $38.41, for a total transaction of $115,230.00. Following the sale, the insider now owns 30,834 shares of the company’s stock, valued at $1,184,333.94. This represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction on Friday, February 28th. The shares were sold at an average price of $34.47, for a total value of $1,723,500.00. Following the completion of the transaction, the chief executive officer now directly owns 494,117 shares of the company’s stock, valued at $17,032,212.99. This represents a 9.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 125,127 shares of company stock valued at $4,139,672 in the last ninety days. 13.88% of the stock is currently owned by corporate insiders.

Zai Lab Stock Performance

Shares of ZLAB stock opened at $33.91 on Thursday. Zai Lab Limited has a 52 week low of $13.48 and a 52 week high of $39.61. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of -12.24 and a beta of 1.08. The company has a 50-day simple moving average of $31.32 and a 200 day simple moving average of $28.07.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). The firm had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. Sell-side analysts forecast that Zai Lab Limited will post -2.58 EPS for the current year.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.